VBL gains on Phase II GBM data

VBL Therapeutics Ltd. (NASDAQ:VBLT) gained $1.63 (29%) to $7.22 on Wednesday after VB-111 met the primary endpoint of improving overall survival (OS) in a Phase II trial to treat recurrent glioblastoma multiforme (GBM).

Patients received VB-111 followed by a combination of VB-111 and Avastin bevacizumab from Roche (SIX:ROG; OTCQX:RHHBY) or Avastin alone after disease progression. The combination led to a statistically significant benefit in median OS of 414 days compared to 235 days for the arm receiving Avastin alone (p=0.05). Full results will be presented at the American Society of Clinical Oncology meeting (ASCO) in May. ...